Patents by Inventor Donald J. Kyle

Donald J. Kyle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Systems and Methods for Attenuating Opioid-Induced Euphoria
    Publication number: 20160074387
    Abstract: Disclosed in certain embodiments is a method of attenuating or preventing opioid-induced euphoria comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: September 14, 2015
    Publication date: March 17, 2016
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Analogs of sodium channel peptide toxin
    Patent number: 9279003
    Abstract: The present invention relates to a peptide and its analogs that selectively inhibit the Nav1.7 sodium channel. The present invention also relates to pharmaceutical compositions useful for treating or preventing a disorder responsive to the blockade of sodium ion channels, especially Nav1.7 sodium ion channels. The present invention further provides methods of treating a disorder responsive to the blockade of sodium channels, and particularly Nav1.7 sodium channels, in a mammal suffering from excess activity of the channels, compositions and methods for providing analgesia by administering a peptide of the invention.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: March 8, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Jae Hyun Park, Donald J. Kyle
  • Peptide Immunogens
    Publication number: 20160022787
    Abstract: The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus.
    Type: Application
    Filed: August 6, 2015
    Publication date: January 28, 2016
    Applicant: Purdue Pharma L.P.
    Inventors: Donald J. KYLE, Daniel A. Soltis, Lynda G. Tussey
  • Buprenorphine analogs
    Patent number: 9221831
    Abstract: The present invention is directed to Buprenorphine Analog compounds of the Formula (I), Formula (IA) or Formula (IB) shown below, wherein R1, R2, R8, R3a, R 3b, G, X, Z and Y are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: December 29, 2015
    Assignee: Purdue Pharma, L.P.
    Inventors: Donald J. Kyle, Laykea Tafesse
  • Aryl substituted indoles and their use as blockers of sodium channels
    Patent number: 9212139
    Abstract: The invention relates to aryl and heteroaryl substituted compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, R1, and Z1-Z5 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: December 15, 2015
    Assignee: Purdue Pharma, L.P.
    Inventors: Donald J. Kyle, Chiyou Ni, Laykea Tafesse, Jiangchao Yao
  • Pyridine compounds as sodium channel blockers
    Patent number: 9120752
    Abstract: The invention relates to substituted pyridine compounds of Formula I: (I) or a pharmaceutically acceptable salt, prodrug, or solvate thereof wherein A1, X, A2, R1a, R1b, R1c, G, and z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: September 1, 2015
    Assignee: Purdue Pharma, L.P.
    Inventors: Donald J. Kyle, Chiyou Ni, Minnie Park, Laykea Tafesse
  • MHC-I restricted epitopes containing non-natural amino acid residues
    Patent number: 9109007
    Abstract: The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus. The exemplary polypeptides are derived from the survivin, hTERT, CYP1B1 and MART-1 antigens.
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: August 18, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Donald J. Kyle, Daniel A. Soltis, Lynda G. Tussey
  • Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
    Publication number: 20150216858
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: February 3, 2015
    Publication date: August 6, 2015
    Inventors: Michelle Hummel, Donald J. Kyle, Garth Whiteside
  • Quarternized buprenorphine analogs
    Patent number: 9096606
    Abstract: The present invention is directed to Buprenorphine Analog compounds of the Formula (I), Formula (IA) or Formula (IB) shown below, wherein R1, R1a, R2, R8, R3a, R3b, G, X, Z, Y, and A® are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: August 4, 2015
    Assignee: Purdue Pharma, L.P.
    Inventor: Donald J. Kyle
  • Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
    Publication number: 20150196551
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: March 26, 2015
    Publication date: July 16, 2015
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
    Publication number: 20150196549
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: March 26, 2015
    Publication date: July 16, 2015
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
    Publication number: 20150196554
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: March 26, 2015
    Publication date: July 16, 2015
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
    Publication number: 20150196553
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: March 26, 2015
    Publication date: July 16, 2015
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
    Publication number: 20150196548
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: March 26, 2015
    Publication date: July 16, 2015
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
    Publication number: 20150196552
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: March 26, 2015
    Publication date: July 16, 2015
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
    Publication number: 20150164887
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: February 26, 2015
    Publication date: June 18, 2015
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
    Publication number: 20150094326
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 2, 2015
    Inventors: Michelle Hummel, Donald J. Kyle, Garth Whiteside
  • 7,8-cyclicmorphinan analogs
    Patent number: 8957084
    Abstract: The application is directed to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein Cy, R1a-R3a, R4a, and R4b are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: February 17, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Donald J. Kyle, Laykea Tafesse, Xiaoming Zhou
  • Systems and methods for treating an opioid-induced adverse pharmacodynamic response
    Patent number: 8946253
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: February 3, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • QUARTERNIZED BUPRENORPHINE ANALOGS
    Publication number: 20140364448
    Abstract: The present invention is directed to Buprenorphine Analog compounds of the Formula (I), Formula (IA) or Formula (IB) shown below, wherein R1, R1a, R2, R8, R3a, R3b, G, X, Z, Y, and A® are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.
    Type: Application
    Filed: December 7, 2012
    Publication date: December 11, 2014
    Applicant: PURDUE PHARMA L.P.
    Inventor: Donald J. Kyle